RPL13A

Across TCGA pan-cancer cohorts, RPL13A mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPL13A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RPL13A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RPL13A is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, CCRCC, and COAD are the cancer types where RPL13A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL13A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.292	<.001	12	view →
CCRCC	Female	III,IV	+0.830	<.001	11	view →
COAD	Male	III,IV	+0.508	<.001	11	view →
PDAC	Female	All	−0.867	<.001	7	view →
LSCC	Male	III,IV	+0.385	<.001	7	view →
LUAD	Male	All	+0.123	.002	3	view →
OV	All	All	+0.565	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPL13A–HNSC

Open the HNSC breakdown →